Novo Nordisk ADR (NYSE: NVO)’s stock price has soared by 0.74 in relation to previous closing price of 68.51. Nevertheless, the company has seen a loss of -1.00% in its stock price over the last five trading days. zacks.com reported 2025-06-30 that Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is It Worth Investing in Novo Nordisk ADR (NYSE: NVO) Right Now?
Novo Nordisk ADR (NYSE: NVO) has a higher price-to-earnings ratio of 20.47x compared to its average ratio, The 36-month beta value for NVO is at 0.64. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 5 as “hold,” and 1 as “sell.”
The public float for NVO is 3.37B, and currently, shorts hold a 0.79% of that float. The average trading volume for NVO on July 01, 2025 was 10.32M shares.
NVO’s Market Performance
The stock of Novo Nordisk ADR (NVO) has seen a -1.00% decrease in the past week, with a -0.63% drop in the past month, and a -0.40% fall in the past quarter. The volatility ratio for the week is 1.87%, and the volatility levels for the past 30 days are at 2.20% for NVO. The simple moving average for the past 20 days is -6.07% for NVO’s stock, with a -22.91% simple moving average for the past 200 days.
Analysts’ Opinion of NVO
Many brokerage firms have already submitted their reports for NVO stocks, with BMO Capital Markets repeating the rating for NVO by listing it as a “Market Perform.” The predicted price for NVO in the upcoming period, according to BMO Capital Markets is $64 based on the research report published on April 17, 2025 of the current year 2025.
NVO Trading at 0.27% from the 50-Day Moving Average
After a stumble in the market that brought NVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.72% of loss for the given period.
Stock Fundamentals for NVO
Current profitability levels for the company are sitting at:
- 0.45 for the present operating margin
- 0.84 for the gross margin
The net margin for Novo Nordisk ADR stands at 0.35. The total capital return value is set at 0.53. Equity return is now at value 87.53, with 26.37 for asset returns.
Based on Novo Nordisk ADR (NVO), the company’s capital structure generated 0.46 points at debt to capital in total, while cash flow to debt ratio is standing at 1.11. The debt to equity ratio resting at 0.86. The interest coverage ratio of the stock is 17.84.
Currently, EBITDA for the company is 137.38 billion with net debt to EBITDA at 0.5. When we switch over and look at the enterprise to sales, we see a ratio of 6.77. The receivables turnover for the company is 3.51for trailing twelve months and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.74.
Conclusion
In conclusion, Novo Nordisk ADR (NVO) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
